Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability And Pharmacodynamics of Subcutaneous Immunotherapy With DM-101PX in Subjects With Birch Pollen Allergy

NCT07898800 is registered in ClinicalTrials.gov with Desentum Oy as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07898800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability And Pharmacodynamics of Subcutaneous Immunotherapy With DM-101PX in Subjects With Birch Pollen Allergy
Lead sponsor
Desentum Oy
Phase
Phase 1
Overall status
Recruiting
Start date
October 29, 2026
Completion date
May 31, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

birch pollen allergy

Arms

As registered; 8 arms.

  • DM-101PX for cohort 1 ExperimentalDM-101PX

    Weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks with dose escalation starting from 0.2 µg with slightly varying injection volumes.

  • Placebo for cohort 1 Placebo comparatorPlacebo

    Weekly subcutaneous administration of Placebo for 10 weeks

  • Experimental: DM-101PX for cohort 2 ExperimentalDM-101PX

    Weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks with dose escalation starting from 0.2 µg with varying injection volumes

  • Placebo for cohort 2 Placebo comparatorPlacebo

    Weekly subcutaneous administration of Placebo for 10 weeks

  • Experimental: DM-101PX for cohort 3 ExperimentalDM-101PX

    Weekly subcutaneous administration of ascending doses of DM-101PX for 10 weeks with regimens consisting of 2 initial placebo s.c. injections, followed by 8 s.c. injections with escalating doses starting from 0.2 µg and with varying injection volumes.

+3 more arms

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Treatment Emergent Adverse Events From the first dose to until 3 months from the last dose

    Occurrence of treatment emergent adverse events

  • Adverse Events of Special Interest From the first dose to until 3 months from the last dose

    Occurrence of local injection site reactions and systemic allergic reactions

Lead sponsor's other trials

Desentum Oy, most recent start first.